PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
PepGen Inc. (Nasdaq: PEPG) has appointed Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development, effective immediately. Dr. Streck brings over 20 years of experience in drug development, regulatory, and medical affairs leadership to the clinical-stage biotechnology company. His impressive track record includes five IND approvals, six global regulatory launches, and nine commercial product launches.
Dr. Streck's extensive experience spans both large and small publicly traded biopharmaceutical companies, including roles as Chief Medical Officer at Albireo Pharma, Arena Pharmaceuticals, Alder Biopharmaceuticals, and Insmed. He has also held positions at GSK, Shire, and Amgen. This appointment comes at a important time for PepGen as they advance four active clinical trials and expand their pipeline of preclinical candidates in the field of oligonucleotide therapies for severe neuromuscular and neurological diseases.
PepGen Inc. (Nasdaq: PEPG) ha nominato Paul Streck, M.D., MBA come Vice Presidente Esecutivo e Responsabile della Ricerca e Sviluppo, con effetto immediato. Il Dott. Streck porta con sé oltre 20 anni di esperienza nello sviluppo di farmaci, nella leadership negli affari regolatori e medici, all'interno dell’azienda biotecnologica in fase clinica. Il suo impressionante curriculum include cinque approvazioni IND, sei lanci regolatori globali e nove lanci di prodotti commerciali.
L'ampia esperienza del Dott. Streck spazia tra grandi e piccole aziende biofarmaceutiche quotate in borsa, con ruoli come Direttore Medico presso Albireo Pharma, Arena Pharmaceuticals, Alder Biopharmaceuticals e Insmed. Ha anche ricoperto posizioni presso GSK, Shire e Amgen. Questa nomina avviene in un momento importante per PepGen, mentre stanno avanzando quattro trial clinici attivi e ampliando il loro portafoglio di candidati preclinici nel campo delle terapie a oligonucleotide per gravi malattie neuromuscolari e neurologiche.
PepGen Inc. (Nasdaq: PEPG) ha nombrado a Paul Streck, M.D., MBA como vicepresidente ejecutivo y jefe de investigación y desarrollo, con efecto inmediato. El Dr. Streck aporta más de 20 años de experiencia en desarrollo de medicamentos, liderazgo en asuntos regulatorios y médicos a la empresa biotecnológica en etapa clínica. Su impresionante trayectoria incluye cinco aprobaciones IND, seis lanzamientos regulatorios globales y nueve lanzamientos de productos comerciales.
La amplia experiencia del Dr. Streck abarca tanto grandes como pequeñas empresas biofarmacéuticas que cotizan en bolsa, habiendo ocupado cargos como director médico en Albireo Pharma, Arena Pharmaceuticals, Alder Biopharmaceuticals e Insmed. También ha ocupado puestos en GSK, Shire y Amgen. Este nombramiento se produce en un momento importante para PepGen, ya que avanzan en cuatro ensayos clínicos activos y amplían su cartera de candidatos preclínicos en el campo de las terapias de oligonucleótidos para graves enfermedades neuromusculares y neurológicas.
PepGen Inc. (Nasdaq: PEPG)은 Paul Streck, M.D., MBA를 연구 및 개발 책임자 겸 부사장으로 즉시 임명했습니다. Dr. Streck는 임상 단계 생명공학 회사에 20년 이상의 경험을 가지고 있으며, 약물 개발, 규제 및 의학 분야의 리더십을 제공합니다. 그의 인상적인 경력에는 5개의 IND 승인, 6개의 글로벌 규제 런칭, 9개의 상업적 제품 출시가 포함됩니다.
Dr. Streck의 풍부한 경험은 Albireo Pharma, Arena Pharmaceuticals, Alder Biopharmaceuticals 및 Insmed의 최고 의료 책임자 역할을 포함하여 상장된 대형 및 소형 생명공학 회사에서 널리 퍼져 있습니다. 그는 또한 GSK, Shire 및 Amgen에서도 일했습니다. 이 임명은 PepGen이 4개의 활성 임상 시험을 진행하고 심각한 신경근육 및 신경계 질환을 위한 올리고뉴클레오타이드 치료법의 프리클리니컬 후보군을 확장하는 중요한 시점에 이루어졌습니다.
PepGen Inc. (Nasdaq: PEPG) a nommé Paul Streck, M.D., MBA au poste de vice-président exécutif et responsable de la recherche et du développement, avec effet immédiat. Le Dr Streck apporte plus de 20 ans d'expérience dans le développement de médicaments, ainsi que dans les affaires réglementaires et médicales, à l'entreprise biopharmaceutique en phase clinique. Son impressionnant parcours comprend cinq approbations IND, six lancements réglementaires mondiaux et neuf lancements de produits commerciaux.
Le Dr Streck possède une vaste expérience au sein d'entreprises biopharmaceutiques cotées, aussi bien grandes que petites, ayant occupé des postes de directeur médical chez Albireo Pharma, Arena Pharmaceuticals, Alder Biopharmaceuticals et Insmed. Il a également travaillé chez GSK, Shire et Amgen. Cette nomination intervient à un moment crucial pour PepGen, alors qu'ils avancent dans quatre essais cliniques actifs et élargissent leur portefeuille de candidats précliniques dans le domaine des thérapies à oligonucleotides pour des maladies neuromusculaires et neurologiques graves.
PepGen Inc. (Nasdaq: PEPG) hat Paul Streck, M.D., MBA mit sofortiger Wirkung zum Executive Vice President und Leiter der Forschungs- und Entwicklungsabteilung ernannt. Dr. Streck bringt über 20 Jahre Erfahrung in der Arzneimittelentwicklung sowie in der Führungsstärke in regulatorischen und medizinischen Angelegenheiten zu dem biopharmazeutischen Unternehmen in der klinischen Phase mit. Sein beeindruckender Leistungsausweis umfasst fünf IND-Zulassungen, sechs globale regulatorische Markteinführungen und neun kommerzielle Produkteinführungen.
Die umfangreiche Erfahrung von Dr. Streck erstreckt sich über große und kleine börsennotierte Biopharma-Unternehmen, darunter verschiedene Positionen als Chief Medical Officer bei Albireo Pharma, Arena Pharmaceuticals, Alder Biopharmaceuticals und Insmed. Er hatte zudem Positionen bei GSK, Shire und Amgen inne. Diese Ernennung erfolgt zu einem wichtigen Zeitpunkt für PepGen, während sie vier aktive klinische Studien vorantreiben und ihr Pipeline von frühen Kandidaten im Bereich der Oligonukleotidtherapien für schwere neuromuskuläre und neurologische Erkrankungen erweitern.
- Appointment of experienced executive Paul Streck as EVP, Head of R&D
- Dr. Streck brings 20+ years of experience in drug development and medical affairs
- Track record includes 5 IND approvals, 6 global regulatory launches, and 9 commercial product launches
- Company has four active clinical trials ongoing
- None.
“We are very pleased that Paul is joining PepGen at such an important time for the Company,” said James McArthur, Ph.D., President and CEO of PepGen. “Throughout his career, Paul has served in leadership roles across both large and small publicly traded biopharmaceutical companies, with notable accomplishments including five IND approvals, six global regulatory launches, and nine commercial product launches. This breadth of experience has equipped him with institutional knowledge that will be of extreme value to PepGen as we continue to advance our four active clinical trials and growing pipeline of preclinical candidates.”
Dr. Streck has more than 20 years of experience in drug development, regulatory, and medical affairs leadership. Most recently, he served as Chief Medical Officer at Albireo Pharma, a publicly traded rare disease biotechnology company acquired by Ipsen in March 2023. Previously, Dr. Streck was Chief Medical Officer at Arena Pharmaceuticals, a publicly traded immuno-inflammatory biotechnology company acquired by Pfizer in March 2022. Before that, he served as Chief Medical Officer at Alder Biopharmaceuticals, acquired by Lundbeck Pharmaceuticals in October 2020, and as the Chief Medical Officer of Insmed, advancing the company from clinical to commercial stage. Previous biopharmaceutical experience includes progressive roles at GSK, Shire, and Amgen, as well as 10 years in academic medical practice.
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit www.pepgen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820703812/en/
Investor Contact
Dave Borah, CFA
SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media Contact
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Source: PepGen Inc.
FAQ
Who is Paul Streck and what is his new role at PepGen (PEPG)?
What is Paul Streck's background and experience in the biopharmaceutical industry?
How many clinical trials does PepGen (PEPG) currently have active?
What are PepGen's (PEPG) main areas of focus in biotechnology?
